Start here if you're new
what it is
Wave builds RNA medicines that try to fix disease-causing genetic messages.
how it gets paid
Last year Wave Life Sciences made $43M in revenue.
why growth slowed
Revenue fell 60.5% last year. Revenue was up 105% vs. prior year, but the quarter still showed a deeper loss.
what just happened
Revenue hit $18M, but EPS stayed at -$0.92 and the loss story did not clean up.
At a glance
B balance sheet — gets the job done, barely
45/100 earnings predictability — expect surprises
-$0.70 fy2024 eps est
$108M fy2024 rev est
n/a operating margin
xvary composite: 48/100 — below average
What they do
Wave builds RNA medicines that try to fix disease-causing genetic messages.
PRISM is a discovery engine (a reusable lab system) feeding 5 named programs. That means 5 shots at a win instead of 1, which is a better setup than a single-bet biotech. You are paying for 287 people to keep one machine making the next molecule, while the company still only has $43M in annual revenue.
How they make money
$43M
annual revenue · revenue declined -60.5% last year
total revenue
$43M
60.5%
The products that matter
lead RNA drug candidate
WVE-006
mid-2026 regulatory feedback
This is the lead alpha-1 antitrypsin deficiency program, and management expects feedback on a potential accelerated approval pathway in mid-2026. In a $2.45B stock, that date matters more than a single quarter of revenue.
lead catalyst
early obesity program
WVE-007
2026 trial start expected
New clinical trials are expected to start in 2026 as an add-on to existing obesity drugs. Early-stage obesity assets get attention fast, and WVE's 52-week range of $5–$22 tells you how violently sentiment can move.
next wave
drug discovery platform
PRISM Platform
powers the pipeline
PRISM is the chemistry engine behind Wave's stereopure oligonucleotide programs. The pitch is broad. The current financial proof is narrow: just $42.73M of trailing revenue against a $2.45B market value.
platform risk
Key numbers
$43M
annual revenue
That is the whole business base right now, which is tiny next to a roughly $2B market cap.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. The company lost far more than it sold, which tells you the growth story is still expensive.
$11M
long-term debt
The balance sheet is not drowning in debt, so the real pressure comes from burns and trial costs, not leverage.
1.05
beta
The stock moves about like the market, which means the biotech drama is coming from the company, not just the tape.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $11M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for WVE right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $18M, but EPS stayed at -$0.92 and the loss story did not clean up.
Revenue was up 105% vs. prior year, but the quarter still showed a deeper loss. Gross margin was -80.9%, which means the company was still losing money on what it sold.
$18M
revenue
$0.92
eps
80.9%
gross margin
the number that mattered
The $18M revenue print mattered most because it was up 105% vs. prior year, even though losses were still brutal.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is WVE-006 failing to earn a credible regulatory path in alpha-1 antitrypsin deficiency.
med
WVE-006 clinical and regulatory disappointment
You are paying a $2.45B market value for a company with $42.73M of trailing revenue because investors believe the lead program can matter. If mid-2026 feedback disappoints, the multiple has nothing solid to lean on.
A weaker path to approval would directly challenge the premium 22.6x sales valuation.
med
Revenue is milestone-driven and unstable
Latest quarterly sales fell to $17.24M from $83.75M a year earlier. Collaboration revenue was down 79.4%, and product / other revenue fell 60.5%.
This business can look smaller very quickly when partner payments do not line up.
med
Losses still dominate the income statement
Trailing net income was -$204.4M, Q2 2025 gross margin was -80.88%, and net loss hit $50.5M in that quarter. Debt is low at $11M, but low debt does not solve operating losses.
If losses keep widening, the market starts thinking about financing risk long before commercialization arrives.
med
Crowded short positioning adds volatility
Short interest sits at 9.54% of float, or 13.65M shares. That is enough to amplify every data point, good or bad.
You can get sharp upside on good news, but the same setup cuts hard when a catalyst misses.
$42.73M of trailing revenue and -$204.4M of trailing net income do not support a $2.45B valuation by themselves. The pipeline has to do that job.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
mid-2026 WVE-006 feedback
This is the key date. If regulators signal a credible accelerated approval path, the valuation can keep pretending the future is close.
trend
revenue volatility, not revenue growth
Quarterly sales fell from $83.75M to $17.24M from a year earlier. In biotech, swings like that usually mean milestones moved, not demand changed.
metric
short interest at 9.54%
13.65M shares are sold short. That is enough fuel for a squeeze if the science hits, and enough skepticism to punish weak readouts.
risk
WVE-007 enters a crowded obesity lane
New trials are expected in 2026. The opportunity is obvious. So is the bar for relevance in obesity now.
Analyst rankings
earnings predictability
45 / 100
in human-speak, analysts do not have a smooth model here because milestone revenue and pipeline news can move the numbers fast.
risk rank
3
Middle of the pack on broad risk scoring. Better than many tiny biotechs, but this is still a catalyst-driven stock.
beta
1.05
Beta measures market sensitivity. In plain English: WVE tends to move with the market, then clinical headlines add their own chaos.
source: institutional data
Institutional activity
institutional ownership data for WVE is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$18
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive